Minocycline-induced lupus - A systematic review

被引:65
|
作者
Schlienger, RG [1 ]
Bircher, AJ
Meier, CR
机构
[1] Univ Basel Hosp, Div Clin Pharmacol, Basel Pharmacoepidemiol Unit, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Div Dermatol, CH-4031 Basel, Switzerland
[3] Univ Basel, Dept Pharm, Inst Pharmacotherapy, CH-4003 Basel, Switzerland
[4] Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA USA
关键词
minocycline; auto-immune diseases; drug-induced lupus;
D O I
10.1159/000018387
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Minocycline has increasingly been associated with different adverse auto-immune reactions including drug-induced lupus, Objective: To identify the scope of minocycline-induced lupus and to characterise its typical features. Methods: Comprehensive Medline and Embase search of the English and non-English literature for case reports of minocyctine-induced lupus. Results: We included 57 cases of minocycline-induced lupus (mean age +/- SD at onset: 21.6 +/- 8.6 years, median time of exposure: 19 months, range 3 days to 6 years). All patients showed the clinical features of polyarthralgia/ polyarthritis often accompanied by liver abnormalities. Twelve patients had evidence of dermatological manifestations (i.e rash, livedo reticularis, oral ulceration, subcutaneous nodules, alopecia). The ANA test was positive in all patients. Conclusion: Long-term exposure to minocycline may be associated with drug-induced lupus. Baseline and periodic liver function and ANA tests accompanied by appropriate clinical monitoring are suggested for patients receiving long-term minocycline therapy. Copyright (C) 2000 S. Karger AG,Basel.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 50 条
  • [1] Minocycline-induced lupus
    Farver, DK
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (10) : 1160 - 1163
  • [2] Minocycline-induced lupus
    Hasegawa, Shinya
    Craig, Steven M.
    Suzuki, Hiroyuki
    BMJ CASE REPORTS, 2024, 17 (12)
  • [3] Minocycline-induced lupus: clinical features and response to rechallenge
    Lawson, TM
    Amos, N
    Bulgen, D
    Williams, BD
    RHEUMATOLOGY, 2001, 40 (03) : 329 - 335
  • [4] Minocycline-induced lupus-like disease
    Leydet, H
    Armingeat, T
    Pham, T
    Lafforgue, P
    REVUE DE MEDECINE INTERNE, 2006, 27 (01): : 72 - 75
  • [5] Minocycline-induced clinical and biological lupus-like disease
    Tournigand, C
    Généreau, T
    Prudent, M
    Diemert, MC
    Herson, S
    Chosidow, O
    LUPUS, 1999, 8 (09) : 773 - 774
  • [6] Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis
    Angulo, JM
    Sigal, LH
    Espinoza, LR
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1998, 28 (03) : 187 - 192
  • [7] Respiratory distress due to minocycline-induced pulmonary lupus
    Christodoulou, CS
    Emmanuel, P
    Ray, RA
    Good, RA
    Schnapf, BM
    Cawkwell, GD
    CHEST, 1999, 115 (05) : 1471 - 1473
  • [8] MINOCYCLINE-INDUCED DERMATOMYOSITIS
    Geddes, Maiya R.
    Sinnreich, Michael
    Chalk, Colin
    MUSCLE & NERVE, 2010, 41 (04) : 547 - 549
  • [9] Minocycline-Induced Hyperpigmentation
    Skorin, Leonid, Jr.
    Norberg, Stephanie
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2018, 118 (07): : 492 - 492
  • [10] Minocycline-Induced Hyperpigmentation
    Figueiredo, Carolina
    Xavier, Maria Manuel
    ACTA MEDICA PORTUGUESA, 2023, 36 (09) : 605 - 606